An Introduction to DILIsym ® Software, a Mechanistic Mathematical Representation of Drug-Induced Liver Injury

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Chemistry, Medicine, Mathematics

• Identifiers
  DOI 10.1007/978-1-4939-7677-5_6
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanistic Modelling of Drug-Induced Liver Injury: Investigating the Role of Innate Immune Responses

  2017cited by this paper
• The role of quantitative systems pharmacology modeling in the prediction and explanation of idiosyncratic drug-induced liver injury.

  2017cited by this paper
• Systems pharmacology modeling of drug‐induced hyperbilirubinemia: Differentiating hepatotoxicity and inhibition of enzymes/transporters

  2017cited by this paper
• Sandwich-Cultured Hepatocytes as a Tool to Study Drug Disposition and Drug-Induced Liver Injury.

  2016cited by this paper
• Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym®, a Mechanistic Model of Drug‐Induced Liver Injury

  2016cited by this paper
• Basolateral Efflux Transporters: A Potentially Important Pathway for the Prevention of Cholestatic Hepatotoxicity

  2016cited by this paper
• Pillars Article: IL-10 Inhibits Cytokine Production by Activated Macrophages. J. Immunol. 1991. 147: 3815-3822.

  2016cited by this paper
• A Systematic Nomenclature for the Redox States of High Mobility Group Box (HMGB) Proteins

  2014cited by this paper
• A Mechanistic Model of Drug-Induced Liver Injury Aids the Interpretation of Elevated Liver Transaminase Levels in a Phase I Clinical Trial

  2014cited by this paper
• Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury

  2014cited by this paper
• Use of a systems model of drug-induced liver injury (DILIsym(®)) to elucidate the mechanistic differences between acetaminophen and its less-toxic isomer, AMAP, in mice.

  2014cited by this paper
• Systems Pharmacology Modeling Predicts Delayed Presentation and Species Differences in Bile Acid-Mediated Troglitazone Hepatotoxicity

  2014cited by this paper
• JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation

  2014cited by this paper
• Mechanistic Modeling Reveals the Critical Knowledge Gaps in Bile Acid–Mediated DILI

  2014cited by this paper
• The Roles of MRP2, MRP3, OATP1B1, and OATP1B3 in Conjugated Hyperbilirubinemia

  2014cited by this paper
• MITOsym®: A Mechanistic, Mathematical Model of Hepatocellular Respiration and Bioenergetics

  2014cited by this paper
• Assessment of gadoxetate DCE-MRI as a biomarker of hepatobiliary transporter inhibition

  2013cited by this paper
• A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.

  2013cited by this paper
• Early Identification of Clinically Relevant Drug Interactions With the Human Bile Salt Export Pump (BSEP/ABCB11)

  2013cited by this paper
• TLR activation regulates damage‐associated molecular pattern isoforms released during pyroptosis

  2012cited by this paper
• An Analysis of N-Acetylcysteine Treatment for Acetaminophen Overdose Using a Systems Model of Drug-Induced Liver Injury

  2012cited by this paper
• Gap junction inhibition prevents drug-induced liver toxicity and fulminant hepatic failure

  2012cited by this paper
• Novel role of PKR in inflammasome activation and HMGB1 release

  2012cited by this paper
• Assessment of drug-induced mitochondrial dysfunction via altered cellular respiration and acidification measured in a 96-well platform

  2012cited by this paper
• Organotypic liver culture models: Meeting current challenges in toxicity testing

  2012cited by this paper
• A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity.

  2012cited by this paper
• Targeted profiling of circulating and hepatic bile acids in human, mouse, and rat using a UPLC-MRM-MS-validated method[S]

  2012cited by this paper
• FXR and PXR: potential therapeutic targets in cholestasis.

  2012cited by this paper
• The Effects of Heparins on the Liver: Application of Mechanistic Serum Biomarkers in a Randomized Study in Healthy Volunteers

  2012cited by this paper
• Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release

  2012cited by this paper
• Identification of urinary microRNA profiles in rats that may diagnose hepatotoxicity.

  2012cited by this paper
• In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI

  2012cited by this paper
• In Vitro Inhibition of the Bile Salt Export Pump Correlates with Risk of Cholestatic Drug-Induced Liver Injury in Humans

  2012cited by this paper
• High mobility group B1 impairs hepatocyte regeneration in acetaminophen hepatotoxicity

  2012cited by this paper
• Impact of microdosing clinical study -- why necessary and how useful?

  2011cited by this paper
• Susceptibility to simvastatin-induced toxicity is partly determined by mitochondrial respiration and phosphorylation state of Akt.

  2011cited by this paper
• The role of CYP3A4 in amiodarone-associated toxicity on HepG2 cells.

  2011cited by this paper
• Profile of serum bile acids in non-cholestatic volunteers: gender-related differences in response to fenofibrate

  2011cited by this paper
• Quantitative analyses and transcriptomic profiling of circulating messenger RNAs as biomarkers of rat liver injury

  2010cited by this paper
• Cell based approaches for evaluation of drug-induced liver injury.

  2010cited by this paper
• Utilization of cytokeratin-based biomarkers for pharmacodynamic studies

  2010cited by this paper
• Bile salts and cholestasis.

  2010cited by this paper
• Mechanism-based bioanalysis and biomarkers for hepatic chemical stress

  2009cited by this paper
• Constitutive Androstane Receptor-Mediated Changes in Bile Acid Composition Contributes to Hepatoprotection from Lithocholic Acid-Induced Liver Injury in Mice

  2009cited by this paper
• In silico toxicology for the pharmaceutical sciences.

  2009cited by this paper
• Antioxidative and hepatoprotective effects of magnolol on acetaminophen-induced liver damage in rats

  2009cited by this paper
• High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo.

  2009cited by this paper
• Bile-acid-induced cell injury and protection.

  2009cited by this paper
• The current state of serum biomarkers of hepatotoxicity.

  2008cited by this paper
• Superiority of serum type-I arginase and ornithine carbamyltransferase in the detection of toxicant-induced acute hepatic injury in rats.

  2008cited by this paper
• Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein.

  2008cited by this paper
• Healthy animals and animal models of human disease(s) in safety assessment of human pharmaceuticals, including therapeutic antibodies.

  2007cited by this paper
• Activation of LXRs prevents bile acid toxicity and cholestasis in female mice

  2007cited by this paper
• Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione.

  2006cited by this paper
• ‘Hy's law,’ the ‘Rezulin Rule,’ and other predictors of severe drug‐induced hepatotoxicity: putting risk‐benefit into perspective

  2006cited by this paper
• Liver enzyme alteration: a guide for clinicians

  2005cited by this paper
• Identification and functional characterization of the natural variant MRP3-Arg1297His of human multidrug resistance protein 3 (MRP3/ABCC3).

  2004cited by this paper
• Transport Activity of Human MRP3 Expressed in Sf9 Cells: Comparative Studies with Rat MRP3

  2004cited by this paper
• S-Adenosylmethionine Protects against Acetaminophen-Induced Hepatotoxicity in Mice

  2004cited by this paper
• Bacterial endotoxin stimulates macrophages to release HMGB1 partly through CD14‐ and TNF‐dependent mechanisms

  2004cited by this paper
• Differentiation between Cell Death Modes Using Measurements of Different Soluble Forms of Extracellular Cytokeratin 18

  2004cited by this paper
• S-Adenosylmethionine (SAMe) attenuates acetaminophen hepatotoxicity in C57BL/6 mice.

  2004cited by this paper
• Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion

  2003cited by this paper
• Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin.

  2003cited by this paper
• Hepatoprotective effect of Himoliv, a polyherbal formulation in rats.

  2003cited by this paper
• Bile salt transporters.

  2002cited by this paper
• Hepatic Uptake of Bilirubin and Its Conjugates by the Human Organic Anion Transporter SLC21A6*

  2001cited by this paper
• Concordance of the toxicity of pharmaceuticals in humans and in animals.

  2000cited by this paper
• Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2

  1999cited by this paper
• Biomarkers of liver regeneration allow early prediction of hepatic recovery after acute necrosis.

  1999cited by this paper
• Reprogramming of lipopolysaccharide-primed macrophages is controlled by a counterbalanced production of IL-10 and IL-12.

  1998cited by this paper
• Caspase Cleavage of Keratin 18 and Reorganization of Intermediate Filaments during Epithelial Cell Apoptosis

  1997cited by this paper
• ATP depletion rather than mitochondrial depolarization mediates hepatocyte killing after metabolic inhibition.

  1994cited by this paper
• A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini.

  1992cited by this paper
• IL-10 inhibits cytokine production by activated macrophages.

  1991cited by this paper
• Coordinated induction of autocrine tumor necrosis factor and interleukin 1 in normal human monocytes and the implications for monocyte-mediated cytotoxicity.

  1990cited by this paper
• Histopathological changes in the liver following a paracetamol overdose: Correlation with clinical and biochemical parameters

  1975cited by this paper

• Quantitative systems toxicology: modelling to mechanistically understand and predict drug safety

  2025cites this paper
• Computational Approaches for Drug-Induced Liver Injury (DILI) Prediction: State of the Art and Challenges

  2021cites this paper
• FDA-Industry Scientific Exchange on assessing quantitative systems pharmacology models in clinical drug development: a meeting report, summary of challenges/gaps, and future perspective

  2021cites this paper
• Evaluation framework for systems models

  2021cites this paper
• Quantitative systems toxicology (QST) reproduces species differences in PF‐04895162 liver safety due to combined mitochondrial and bile acid toxicity

  2019cites this paper
• Latest advances in diagnosing and predicting DILI: what was new in 2017?

  2018cites this paper